- Home
- BL vs OLMA Comparison
BL vs OLMA Comparison
Compare BL & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BL | OLMA |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BL | OLMA |
|---|---|---|
| Price | $28.44 | $10.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $56.62 | $44.89 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $177,031,000.00 | N/A |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $10.90 | N/A |
| P/E Ratio | $220.85 | ★ N/A |
| Revenue Growth | ★ 43.78 | N/A |
| 52 Week Low | $24.70 | $3.89 |
| 52 Week High | $59.57 | $36.26 |
Technical Indicators
Market Signals| Indicator | BL | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 23.01 |
| Support Level | $25.49 | $7.79 |
| Resistance Level | $30.93 | $11.54 |
| Average True Range (ATR) | 1.96 | 0.86 |
| MACD | 0.21 | -0.28 |
| Stochastic Oscillator | 41.75 | 0.47 |
Price Performance
Historical ComparisonAbout BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.